The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

This is to inform you that Sagent Pharmaceuticals is recalling **DOCETAXEL INJECTION, USP 160 MG/16 ML (10 MG/ML), NDC 25021-254-16 and 80 MG/8 ML, NDC 25021-254-08.** This recall is being issued out of an abundance of caution to the USER LEVEL. The product is being recalled due to the potential presence of particulate matter from the stopper in the drug product.

Risk Statement: Intravenous administration of an injectable product that contains particulate matter may result in serious adverse events. Potential complications related to injection of particles include inflammation of a vein, granuloma, and blockage of blood vessels in the heart, lungs, or brain which can cause stroke or life-threatening blood clot events. The frequency and severity of these adverse events could vary depending upon a variety of factors including the size and number of particles in the drug product, patient comorbidities (such as age, compromised organ function), and presence or absence of vascular anomalies. To date, Sagent Pharmaceuticals has not received any reports of adverse events related to this recall.

Product	Lot Number	NDC	Expiration Date	Strength
DOCETAXEL INJECTION, USP	F1030001	25021-254-16	12/2024	160 mg/16 mL (10 mg/mL)
	F1040001	25021-254-08	12/2024	80 mg/8 mL (10 mg/mL)